Michael S. Wyzga - 18 Aug 2023 Form 4 Insider Report for X4 Pharmaceuticals, Inc (XFOR)

Role: Director
Signature: /s/ Adam S. Mostafa, attorney-in-fact
Issuer symbol: XFOR
Transactions as of: 18 Aug 2023
Net transactions value: +$29,875
Form type: 4
Filing time: 22 Aug 2023, 16:09:35 UTC
Previous filing: 14 Jun 2023
Next filing: 02 Jan 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	XFOR	Common Stock	Purchase	$29,875	+25,000	+48%	$1.20	76,667	18 Aug 2023	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported in Column 4 is a weighted average price. These shares were purchased in two transactions at $1.195 and $1.20. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price set forth in this footnote.
F2	Of the shares of common stock reported, 48,333 shares represent restricted stock units.

Content

The price reported in Column 4 is a weighted average price. These shares were purchased in two transactions at $1.195 and $1.20. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price set forth in this footnote.

Of the shares of common stock reported, 48,333 shares represent restricted stock units.